PDCD1 and neoplasm: One week after MC38 tumour cell inoculation, the mice were treated with the anti-PD1 mAb, anti-TNFR2 mAb, anti-PD1 plus anti-TNFR2 mAbs, or the immunoglobulin G (IgG) isotype control (Figure 7A).